VolitionRx Limited VNRX · Stock Open VolitionRx Limited in new tab
VolitionRx Limited Analysis (VNRX)
Is VolitionRx Limited a good investment? VolitionRx Limited (VNRX) is currently trading at 0.2649 USD. Market analysts have a consensus price target of 13.62 USD. This suggests a potential upside from current levels.
Earnings Schedule: VolitionRx Limited is expected to release its next earnings report on Nov. 12, 2026. The market consensus estimate for Forward EPS is -0.85.
Investor FAQ
Does VolitionRx Limited pay a dividend?
No, it does not currently pay a dividend.
What asset class is VolitionRx Limited?
VolitionRx Limited is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 12, 2026. The company currently has a trailing EPS of -3.85.
Company Profile
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.
| Split Date | Split Ratio to 1 |
|---|---|
| April 28, 2026 | 1:20 |
Community Discussion